Review article: the antimicrobial effects of rifaximin on the gut microbiota
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Summary: Background: Disruption of the gut microbiota through use of systemic antimicrobials or activation of the mucosal inflammatory response by pathogens can cause dysregulation of the intestinal mucosa. Aim: To explore the mechanisms of action of rifaximin that may underlie its clinical benefits in travellers’ diarrhoea (TD). Methods: A literature search was performed using the terms ‘rifaximin’ and ‘L/105’ in combination with the terms ‘in vitro activity’, ‘diarrhea’, ‘microbiota’ and ‘gut flora’. Results: Rifaximin has been traditionally identified as a nonsystemic, broad‐spectrum, bactericidal antibiotic. Evidence shows that the activity of rifaximin against enteropathogens in this setting is likely enhanced by its increased solubility in the presence of bile acids in the small intestine. Results of clinical studies show that although rifaximin is efficacious in TD, a clinical cure often occurs without apparent bacterial eradication and with minimal effect on the gut microbiota, suggesting an effect of rifaximin other than direct antibiotic activity. Conclusions: Although definitive studies on the effect of rifaximin on the gut microbiota in large cohorts of healthy volunteers or patients have not been published, pre‐clinical studies provide some insight. These studies have shown that rifaximin may have effects on both the pathogen and host, including direct effects on pathogenic bacteria (such as reducing the expression of bacterial virulence factors) and indirect effects on the host (such as inhibiting bacterial attachment and internalisation at the intestinal mucosa and reducing mucosal inflammation).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut microbiota in health and disease
Sekirov, I., Russell, S. L., Antunes, L. C. M., & Finlay, B. B. (2010) · Physiological Reviews · doi:10.1152/physrev.00045.2009 · Cited by 4,182 · cited 8×
“most of which colonise the skin and the genitourinary, gastrointestinal (GI) and respiratory tracts.(1) The GI tract is particularly dense with bacterial cells (e.”
BackgroundInfluentialNF-κB: a key role in inflammatory diseases
Tak, P. P., & Firestein, G. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11830 · Cited by 3,918
The gut microbiota--masters of host development and physiology
Sommer, F., & Bäckhed, F. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro2974 · Cited by 3,681
The gut flora as a forgotten organ
O'Hara, A. M., & Shanahan, F. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400731 · Cited by 2,791
The role of gut microbiota in immune homeostasis and autoimmunity
Wu, H.-J., & Wu, E. (2012) · Gut Microbes · doi:10.4161/gmic.19320 · Cited by 1,426
Brain-gut-microbe communication in health and disease
Grenham, S., Clarke, G., Cryan, J. F., & Dinan, T. G. (2011) · Frontiers in Physiology · doi:10.3389/fphys.2011.00094 · Cited by 952
Xu, D., Gao, J., Gillilland, M., Wu, X., Song, I., Kao, J. Y., & Owyang, C. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.10.026 · Cited by 271 · cited 3×
“tion through its antibiotic properties by altering ileal bacterial communities.(40) Chronically stressed Wistar rats showed a loss of bacterial diversity and a reduction of family groups in the bacterial community of the distal ileum, increased levels of inflammatory cytokines [IL-17,”
BackgroundInfluential
Cited by
Effects of Psychological, Environmental and Physical Stressors on the Gut Microbiota
Karl, J. P., Hatch, A. M., Arcidiacono, S. M., Pearce, S. C., Pantoja-Feliciano, I. G., Doherty, L. A., & Soares, J. W. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02013 · Cited by 530
Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy
Rose, C. F., Amodio, P., Bajaj, J. S., Dhiman, R. K., Montagnese, S., Taylor-Robinson, S. D., Vilstrup, H., & Jalan, R. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.013 · Cited by 470
Koloski, N. A., Jones, M., & Talley, N. J. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13738 · Cited by 318
Antibiotic use and microbiome function
Ferrer, M., Méndez-García, C., Rojo, D., Barbas, C., & Moya, A. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.09.007 · Cited by 299
Weber, D., Jenq, R. R., Peled, J. U., Taur, Y., Hiergeist, A., Koestler, J., Dettmer, K., Weber, M., Wolff, D., Hahn, J., et al. (2017) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2017.02.006 · Cited by 245
Acharya, C., Betrapally, N. S., Gillevet, P. M., Sterling, R. K., Akbarali, H., White, M. B., Ganapathy, D., Fagan, A., Sikaroodi, M., & Bajaj, J. S. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13858 · Cited by 175
Randomised clinical trial: rifaximin versus placebo for the treatment of functional dyspepsia
Tan, V. P. Y., Liu, K. S. H., Lam, F. Y. F., Hung, I. F. N., Yuen, M. F., & Leung, W. K. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13945 · Cited by 143
“There is currently limited data to explain the therapeutic effect of rifaximin in functional dyspepsia or even in IBS.(11) Emerging data which may account for the effectiveness of rifaximin in functional dyspepsia include rifaximin’s role on the gut microbiota as an antibiotic, its proclivity for the duodenum, its act…”
BackgroundInfluentialWeber, D., Hiergeist, A., Weber, M., Dettmer, K., Wolff, D., Hahn, J., Herr, W., Gessner, A., & Holler, E. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy711 · Cited by 92
Metadata
- Authors
- DuPont, H. L.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2015-11-30
- Volume
- 43
- Issue
- S1
- Pages
- 3-10
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2187893519
- Cited by
- 76
- References
- 7
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.